• WisBusiness

Quintessence Biosciences: Meeting with potential partners at 2012 BIO international convention

Contact: Laura E. Strong,
Quintessence Biosciences, Inc.

Quintessence Biosciences: Meeting with potential partners at 2012 BIO international convention

Madison, WI June 15, 2012– Quintessence Biosciences (Quint Bio) will be meeting with potential development partners at the BIO Business Forum at the 2012 BIO International Convention (June 18-21 in Boston). The global conference provides opportunities for biotechnology companies to learn about trends in the industry as well as enabling partnering discussions via a dedicated online and in person system. At the 2011 BIO convention, 21,183 partnering meetings were held between 2,410 companies. QuintBio was among a select group of Wisconsin companies selected for a Small Business Scholarship by BioForward, Wisconsin Economic Development Corporation (WEDC) and Marshfield Clinic. The other Wisconsin biotechnology companies chosen are: Centrose, DNAStar, InvivoSciences, NeoClone, Primorigen, ioGenetics, Scarab Genomics and Stratatech.

"The BIO convention comes at a good point in our Phase I trial of QBI-139, our lead ribonuclease cancer drug," said Dr. Laura Strong, President at QuintBio. “In addition to our innovative approach to cancer therapy, sharing results from our ongoing trial has drawn strong interest from potential partners."

In addition to the Business Forum, Dr. Strong will give a live presentation at the Wisconsin exhibit booth #205 at 4:15 PM on Tuesday June 19. Other presenters at the Wisconsin booth include Kevin Conroy, CEO of Exact Sciences (Monday June 18 at 2 pm). Information about Wisconsin's presence in the BIO exhibit hall, an effort led by WEDC, can be found at wisconsinatbio.com. Wisconsin focused coverage from the convention will be provided at bio.wisbusiness.com and on Twitter through @WisconsinatBIO. The main BIO Convention hashtag is #BIO2012.

About Quintessence Biosciences, Inc.
Quintessence Biosciences (QuintBio) is a private, clinical stage biopharmaceutical company developing novel anti-cancer compounds based on the patented EVade™ Ribonuclease technology. The most advanced lead candidate, QBI-139 is in a Phase 1 clinical trial at The University of Texas M.D. Anderson Cancer Center and The University of Wisconsin Carbone Cancer Center. The company has additional EVade™ Ribonuclease products in earlier stages of development. For additional information, visit http://www.quintbio.com/

wisbusiness.com Social News

Follow Us

Site Sponsors

Copyright ©2018 WisBusiness.com All rights reserved. | WisOpinion.com | WisPolitics.com  |  Website development by wisnet.com LLC  | Website design by Makin’ Hey Communications